The Biotherapies and Bioproduction of Innovative Therapies (BBTI) Research Program (PEPR), launched by the French government in 2021, is one of the major initiatives in the Biotherapies and Bioproduction of Innovative Therapies acceleration strategy of the France 2030 plan.
This research program, whose scientific management has been entrusted to Inserm and CEA, aims to contribute to the development of tomorrow’s biotherapies and associated key technologies.
It also aims to federate the national academic research ecosystem and promotes close links with industry and hospitals.
The PEPR is part of a wider drive to consolidate France’s leadership and competitiveness in this sector research and manufacturing processes.
Latest news
BioSynEurope – Biotherapies & Biomanufacturing: Fron France’s National Initiatives to European Synergies
Building the European biotherapeutics sector together
The PEPR Biotherapies Announces the Laureates from Its Second Call for Projects
Four Projects to Explore New Therapeutic Avenues
Call for applications – Support for Master 2 internship
Opening: January 1, 2026 – Closing: November 24, 2026
Projects
ATHENA
Design improvement of homogeneous Antibody-Radionuclide-Drug Conjugates to reach promising and efficient crossfire treatments of cancersCoordination Dr Aurélie Maisonial-Besset, UMR 1240 IMoST INSERM Université Clermont Auvergne, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Clermont Ferrand (Tutelle : INSERM) Key words Antibody-radionuclide-drug conjugates (ARDC) Cancers Targeted radionuclide therapy Radiosensitization Bioconjugaison Key figures Budget : 1,65 M€ Duration : 4 years…
BACTER-EV-BOOSTER
Multidisciplinary approach to stimulate the bioproduction and engineering of Gram+ bacteria’s Extracellular Vesicles (EVs) for therapeutic applications to treat inflammation
Bioengineered Skin-France
Bioengineering of next-generation skin substitutes for cutaneous regeneration
BIOSCALE
Improving the whole chain of large scale AAV bioproduction through disruptive technologies
CARN
Development of biotherapies based on the local delivery of therapeutic RNAs by hybrid functionalized extracellular vesicles (EVs) for musculoskeletal regeneration
iceTherapies
Directional freezing of biologics in non-toxic conditions to enhance cell therapies’ activity and administration logisticsCoordination Francisco M. Fernandes (Laboratoire de Chimie de la Matière Condensée de Paris – LCMCP, UMR 7574) Sorbonne Université Key words Cryopreservation Directional freezing Cell therapy Non-toxic freezing media Control and observation of the freezing front Key figures Budget : 2,7…
iPSC France
Genomic editing of stable universal pluripotent stem cells for allogeneic cell biotherapies
MONO-CHEM
Chemical biology-enhanced monocyte engineering for innovative cell therapy against solid tumorsCoordination Alexandre Detappe, Equipe de Nanomédecine (Unité biothérapies innovantes, Inserm U1363 ) |Gustave Roussy Key words Monocyte cell therapy Switchable CAR Bioorthogonal chemistry Triple-negative breast cancer Theranostics Key figures Budget : 3 M€ Duration : 4 ans (2026 – 2030) Summary The challenge. Harnessing monocytes,…
MUSCLE
Medication using specialized cell‐targeted lipid nanoparticle encapsulation in neuromuscular disorders
QualAAV
Innovative approaches for quality control to support the industrial deployment of future gene therapy products.
STROMAEV
From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation